StockNews.com Begins Coverage on Aptose Biosciences (NASDAQ:APTO)

StockNews.com assumed coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a report released on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Separately, HC Wainwright restated a “buy” rating and set a $60.00 price target on shares of Aptose Biosciences in a research note on Wednesday, February 12th.

Aptose Biosciences Trading Up 9.9 %

Shares of APTO opened at $3.64 on Tuesday. The firm has a market cap of $234.05 million, a PE ratio of -1.23 and a beta of 0.88. Aptose Biosciences has a 1-year low of $3.11 and a 1-year high of $58.20. The firm has a fifty day simple moving average of $6.09 and a two-hundred day simple moving average of $8.98.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Aptose Biosciences stock. Bleichroeder LP purchased a new position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 2,500,000 shares of the biotechnology company’s stock, valued at approximately $563,000. Bleichroeder LP owned 4.15% of Aptose Biosciences at the end of the most recent reporting period. 26.62% of the stock is currently owned by institutional investors.

About Aptose Biosciences

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.